What are other options for treating thromboangiitis obliterans (TAO) (Buerger disease)?

Updated: Jul 27, 2020
  • Author: Naiem Nassiri, MD; Chief Editor: Vincent Lopez Rowe, MD  more...
  • Print

Autologous bone marrow–derived progenitor cell implantation into ischemic limbs for potentiation of angiogenesis has been performed as an experimental alternative option. Results have been satisfactory, with minimal complication rates. Larger-scale studies and longer follow-up are needed before any firm recommendations can be made about this particular therapeutic option. [9]

Endovascular options for treatment of occlusive lesions in TAO are becoming increasingly popular, with moderate- and long-term success seen in selected patients. [14, 15, 16]

Rodoplu et al retrospectively investigated the efficacy of percutaneous transluminal angioplasty (PTA) for the treatment of critical limb ischemia (CLI) secondary to TAO in 24 patients (46 limbs). [21] Limb salvage was achieved in 21 (87.5%). Revascularization was achieved in 87.5% of the destination arteries at the primary intervention, and the overall technical success rate (including reinterventions) was 95.8%. After PTA, 22 patients showed a clinical response, and mean Rutherford category significantly improved (from 5.2 ± 0.74 to 1.6 ± 0.7). Complete wound healing was achieved in all patients with ischemic ulcers at 3.9 ± 2.6 months after revascularization. Six patients required reinterventions.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!